Allison Wey, a veteran financial communications exec on the agency and corporate sides, has moved to the top post overseeing investor relations and public affairs for Durata Therapeutics, which went public in July.
Wey |
Wey takes a VP title with the Morristown, N.J.-based early stage pharma developer of therapeutics for patients with infectious diseases and acute illnesses.
The three-year-old went public in a $68M offering July 19, but does not yet have any products approved for sale. It previously acquired antibiotic dalbavancin from Pfizer. That drug in in Phase 3 clinical trials.
Wey was recently VP of IR and corporate affairs for Par Pharmaceuticals through its acquisition by TPG. Earlier, she was VP of IR and corporate comms. at Boron, LePore & Associates, senior VP at Edelman financial, and managing director of Hill+Knowlton Strategies’ financial communications group.